In its latest steps to make clinical trials more representative of the real world, FDA plans to release draft guidance related to the implementation of siteless trials and the incorporation of new digital tools. The agency is also increasing its capacity to use machine learning and AI to identify new surrogate endpoints.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,